Pachyonychia congenita and hidradenitis suppurativa: no response to infliximab therapy

Pedraz, J.; Peñas, P.F.; García‐Diez, Amaro

doi:10.1111/j.1468-3083.2008.02691.x

Cited by 18 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 8 case reports (24 patients), only the induction regimen was administered (19, 21,24,25,28,29,32,35). A majority of these (13/24) patients had reported improvement for various periods of time up to 2 years after induction treatment.…”

Section: Infliximab (Refs 19-38mentioning

confidence: 95%

See 1 more Smart Citation

Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors

Haslund¹,

Lee²,

Jemec³

2009

Acta Derm Venerol

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a common inflammatory skin disease. Medical treatment is often disappointing and in severe disease surgery remains the therapy of choice. Extensive surgery may be effective but also mutilating. Patients experience a significant reduction in quality of life and the need for new treatment modalities are urgent. In recent years patients with HS have been treated off-label with tumour necrosis factor-alpha (TNF-alpha) inhibitors with a varying degrees of effect. We performed a systematic review of papers retrieved from two databases (PubMed and Web of Science) using the follow-ing keywords: hidradenitis suppurativa, acne inversa, infliximab, etanercept, and adalimumab. A total of 34 publications were retrieved, describing treatment of 105 patients. Most cases report treatment with infliximab (52/105). A positive treatment outcome was reported in 90/105 cases, with only 7/105 non-responders and 8/105 patients experiencing side-effects. The side-effects were comparable to those seen in other TNF-alpha inhibitor studies. In the majority of cases the treatment was effective when given as a suppressive therapy, but 15/105 cases were described with long-term remission (>or= 3 months) after the end of therapy. In most publications follow-up was, however, insufficient to allow a systematic exploration of this. TNF-alpha inhibitors seem to be effective in the treatment of HS. However, several questions remain to be answered through specific studies. This review has also identified a need for more standardized reporting of the outcomes as well as randomized controlled trials in this disease.

show abstract

Section: Infliximab (Refs 19-38mentioning

confidence: 95%

“…A majority of these (13/24) patients had reported improvement for various periods of time up to 2 years after induction treatment. Six patients showed improvement only under treatment (25,28) and 5 patients reported no improvement (28,29,35). One paper chose a different dosage schedule (23).…”

Section: Infliximab (Refs 19-38mentioning

confidence: 96%

Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors

Haslund¹,

Lee²,

Jemec³

2009

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…Both types show hypertrophic nail changes, focal palmoplantar keratoderma, and follicular keratoses of the elbows and knees. The clinical discrimination between PC‐1 and PC‐II usually depends on the more prominent oral leukokeratosis in PC‐1 or, conversely, on the finding of steatocystoma/pilosebaceous cysts, vellus hair cysts, hair abnormalities, and natal teeth in PC‐II 8,9 . Genetic mutations in keratins K6a and K16 are associated with the PC‐1 phenotype, whereas K6b and K17 mutations are associated with the PC‐II phenotype 1 …”

Section: Discussionmentioning

confidence: 99%

Persistent hoarseness in a patient with pachyonychia congenita: an early sign of laryngeal involvement

et al. 2009

View full text Add to dashboard Cite

“…Only those 15 patients who were initially allocated to infliximab were included. Evidence levels B and C were found in seven 19,43–48 and 34 studies, 49–82 respectively. One study compared the effect of infliximab with another treatment, namely adalimumab 19 .…”

mentioning

confidence: 97%

“…Tertiary endpoints Fourteen studies did not report on AEs 50,52,55,59–61,65,66,69–71,74,78,82 . AEs were observed in 19 studies (Table 2).…”

mentioning

confidence: 99%

Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review

Blok

Hattem

Jonkman

et al. 2013

British Journal of Dermatology

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a difficult disease to treat. Although the pathogenesis of this inflammatory skin disease is largely unknown, the important role of the immune system has been demonstrated in both experimental and clinical studies. Clinicians are therefore increasingly prescribing systemic treatments with immunosuppressive agents, but the more traditionally used systemic retinoids, especially isotretinoin, also remain relatively common therapies. In order to provide an overview of all currently available systemic immunosuppressive agents and retinoids for the treatment of HS, a systematic search was performed using the Medline and Embase databases. All published papers concerning systemic retinoids or immunosuppressive treatments for HS in adults were included. The primary endpoints were the percentages of significant responders, moderate responders and nonresponders. Other endpoints were the relapse rate and adverse events. In total 87 papers were included, comprising 518 patients with HS who were treated with systemic retinoids, biological agents or another immunosuppressive agents, including colchicine, ciclosporin, dapsone or methotrexate. The highest response rates were observed with infliximab, adalimumab and acitretin. Overall, the quality of evidence was low and differed between the agents, making direct comparisons difficult. However, based on the amount of evidence, infliximab and adalimumab were the most effective agents. Acitretin was also effective in HS, although the quality of the evidence was low. The therapeutic effect of isotretinoin is questionable. Randomized controlled trials are needed to confirm the effectiveness of acitretin, and to identify the most effective immunosuppressive agents in HS.

show abstract

Pachyonychia congenita and hidradenitis suppurativa: no response to infliximab therapy

Cited by 18 publications

References 8 publications

Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors

Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors

Persistent hoarseness in a patient with pachyonychia congenita: an early sign of laryngeal involvement

Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review

Contact Info

Product

Resources

About